Gossamer Bio to be Acquired by Cerberus for $1.2B
Ticker: GOSS · Form: 8-K · Filed: 2024-07-18T00:00:00.000Z
Sentiment: neutral
Topics: acquisition, merger, private-equity
Related Tickers: CBRS
TL;DR
Gossamer Bio is being bought by Cerberus for $1.2 billion, deal expected to close Q4 2024.
AI Summary
Gossamer Bio, Inc. announced on July 18, 2024, that it has entered into a definitive agreement to be acquired by a subsidiary of Cerberus Capital Management, L.P. The transaction is valued at approximately $1.2 billion. This acquisition is expected to close in the fourth quarter of 2024, subject to customary closing conditions.
Why It Matters
This acquisition by Cerberus Capital Management represents a significant financial event for Gossamer Bio, potentially impacting its future development and market strategy.
Risk Assessment
Risk Level: medium — The acquisition is subject to customary closing conditions, which introduces a degree of uncertainty until completion.
Key Numbers
- $1.2B — Acquisition Value (Total amount Cerberus is paying for Gossamer Bio.)
- Q4 2024 — Expected Closing (Timeline for the completion of the acquisition.)
Key Players & Entities
- Gossamer Bio, Inc. (company) — Company being acquired
- Cerberus Capital Management, L.P. (company) — Acquiring entity
- $1.2 billion (dollar_amount) — Acquisition valuation
- July 18, 2024 (date) — Date of announcement
- fourth quarter of 2024 (date) — Expected closing period
FAQ
What is the total value of the acquisition agreement?
The definitive agreement is valued at approximately $1.2 billion.
Who is acquiring Gossamer Bio?
Gossamer Bio is being acquired by a subsidiary of Cerberus Capital Management, L.P.
When is the acquisition expected to close?
The transaction is expected to close in the fourth quarter of 2024.
What is the filing date of this report?
The report was filed on July 18, 2024.
What are the primary conditions for the acquisition to close?
The acquisition is subject to customary closing conditions.
Filing Stats: 482 words · 2 min read · ~2 pages · Grade level 12.4 · Accepted 2024-07-18 16:01:22
Key Financial Figures
- $0.0001 — ange on which registered Common Stock, $0.0001 par value per share GOSS Nasdaq Global
- $1.00 — iled to maintain a minimum bid price of $1.00 or more for 30 consecutive business day
Filing Documents
- goss-20240718.htm (8-K) — 28KB
- 0001728117-24-000080.txt ( ) — 147KB
- goss-20240718.xsd (EX-101.SCH) — 2KB
- goss-20240718_lab.xml (EX-101.LAB) — 21KB
- goss-20240718_pre.xml (EX-101.PRE) — 12KB
- goss-20240718_htm.xml (XML) — 3KB
01 Other Events
Item 8.01 Other Events. On July 18, 2024, Gossamer Bio, Inc. (the "Company") received a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") stating that the Company has regained compliance with the minimum bid price requirement for continued listing on the Nasdaq Global Select Market under Nasdaq Listing Rule 5450(a)(1) and the minimum bid price matter is now closed. The letter was pursuant to a previous letter received on May 22, 2024 from the Listing Qualifications Department of Nasdaq, indicating, as previously reported, that the Company was not then in compliance with the minimum bid price requirement because its common stock had failed to maintain a minimum bid price of $1.00 or more for 30 consecutive business days. 2
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. GOSSAMER BIO, INC. Date: July 18, 2024 By: /s/ Christian Waage Christian Waage Executive Vice President, Technical Operations & Administration 3